🇺🇸 FDA
Patent

US 12227746

Compounds and methods for modulating SCN2A

granted A61PA61P25/00

Quick answer

US patent 12227746 (Compounds and methods for modulating SCN2A) held by Ionis Pharmaceuticals, Inc. expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P25/00